44.76% -0.329

Avenue Therapeutics Inc (ATXI)

Überblick Nachrichten Preisverlauf Financials Warum fällt ATXI? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Avenue Therapeutics Inc Stock (ATXI) Company Profile

Avenue Therapeutics Inc

Healthcare (1119)

Biotechnology (622)

Nächster Verdiensttermin

Neueste SEC-Einreichungen

ATXI's Discussions on Twitter

Vergleichen Sie ATXI mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ATXI Avenue Therapeutics Inc	0.406	0	0	-10.38M	-12.45M	-3.81
VRTX Vertex Pharmaceuticals Inc	477.07	118.84B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	759.04	79.20B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	828.39	50.42B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	359.89	47.29B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	335.43	37.55B	4.98B	69.59M	525.67M	0.5197

Avenue Therapeutics Inc Aktie (ATXI) Neueste Nachrichten

Finanzdaten der Avenue Therapeutics Inc-Aktie (ATXI)

Avenue Therapeutics Inc (ATXI)

Avenue Therapeutics Inc Stock (ATXI) Company Profile

Vergleichen Sie ATXI mit anderen Aktien

Avenue Therapeutics Inc Aktie (ATXI) Neueste Nachrichten

Century Therapeutics (NASDAQ:IPSC) Stock Rating Upgraded by Wall Street Zen - MarketBeat

Pacific Heights Asset Management LLC Raises Stake in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat

TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Fate Therapeutics (NASDAQ:FATE) Stock Price Crosses Above 50-Day Moving AverageHere's What Happened - MarketBeat

Maze Therapeutics (NASDAQ:MAZE) Cut to "Sell" at Wall Street Zen - MarketBeat

More cash flows into biotechs during conference week: Finance Report - BioCentury

Aptevo Therapeutics (NASDAQ: APVO) seeks OK for $60M SEPA share sales - Stock Titan

Market Recap: Can Ernexa Therapeutics Inc continue delivering strong returnsJuly 2025 PostEarnings & Low Risk High Reward Ideas - baoquankhu1.vn

Avenue Therapeutics shareholders elect directors, ratify KPMG auditor - MSN

Early ZYCUBO treatment cut death risk nearly 80% in children with Menkes - Stock Titan

Capricor Therapeutics (NASDAQ:CAPR) Cut to Sell at Wall Street Zen - MarketBeat

Kyverna Therapeutics (NASDAQ:KYTX) Upgraded to "Hold" at Wall Street Zen - MarketBeat

Mersana Therapeutics (NASDAQ:MRSN) Upgraded at Wall Street Zen - MarketBeat

Is PTC Therapeutics Inc. stock a defensive play in 20252025 Price Targets & Smart Investment Allocation Tips - Улправда

Capricor Therapeutics (NASDAQ:CAPR) Upgraded at Wall Street Zen - MarketBeat

PTC Therapeutics (NASDAQ:PTCT) Upgraded to Buy at Wall Street Zen - MarketBeat

Avenue Therapeutics Provides Regulatory Update on IV Tramadol and Other Corporate Updates - ADVFN

Fortress Biotech, Cyprium Therapeutics and Sentynl Therapeutics Announce CUTX-101, Copper Histidinate, Data to be Presented at 2022 American College of Medical Genetics Annual Clinical Genetics Meeting - ADVFN

Avenue Therapeutics (ATXI) investors reelect six directors and ratify KPMG for 2025 - Stock Titan

Axsome Therapeutics shares gain 1.4% premarket after FDA grants priority review for co's Alzheimer's agitation drug - marketscreener.com

FDA supports Axsome’s NDA submission for narcolepsy drug AXS-12 By Investing.com - Investing.com Australia

ATXI: All directors were elected and KPMG LLP was ratified as auditor for 2025 - TradingView — Track All Markets

ATXI: All director nominees were elected and KPMG LLP was ratified as auditor for 2025 - TradingView — Track All Markets

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Dyne Therapeutics (NASDAQ:DYN) Stock Rating Lowered by Wall Street Zen - MarketBeat

vTv Therapeutics (NASDAQ:VTVT) Upgraded at Wall Street Zen - MarketBeat

Vera Therapeutics (VERA) Stock Dips in Thin Post‑Christmas Trading as Wall Street Weighs FDA Filing, $300M Raise, and IgA Nephropathy Competition - TechStock²

NexImmune (NASDAQ:NEXI) versus Avenue Therapeutics (NASDAQ:ATXI) Head-To-Head Comparison - Defense World

The Philippines - AstraZeneca

Avenue Therapeutics, Inc.Common Stock (NQ: ATXI - FinancialContent

Form 424B3 Ovid Therapeutics Inc. - StreetInsider

Will Neumora Therapeutics Inc. stock benefit from AI adoptionOil Prices & Weekly Setup with High ROI Potential - Улправда

Axsome Therapeutics stock hits all-time high at 152.98 USD - Investing.com

Axsome Therapeutics stock hits all-time high at 152.98 USD By Investing.com - Investing.com Australia

Axsome Therapeutics (AXSM) Gets a Buy from Jefferies - The Globe and Mail

Avenue Therapeutics (ATXI) plans resale of 731,061 warrant-linked shares - Stock Titan

[RW] AVENUE THERAPEUTICS, INC. SEC Filing - Stock Titan

Fortress Biotech (Nasdaq: FBIO): FDA accepts Class 1 resubmission, CUTX-101 PDUFA Jan. 14, 2026 - Stock Titan

Spero Therapeutics (NASDAQ:SPRO) Upgraded to "Buy" at Wall Street Zen - MarketBeat

TG Therapeutics (NASDAQ:TGTX) Rating Increased to Buy at Wall Street Zen - MarketBeat

RBC Capital Sticks to Its Buy Rating for Axsome Therapeutics (AXSM) - The Globe and Mail

Sionna Therapeutics (NASDAQ:SION) Upgraded at Wall Street Zen - MarketBeat

Axsome Confident On Regulatory, Commercial Outlook for Alzheimer's Agitation Drug Candidate, RBC Says - marketscreener.com

Vera Therapeutics (VERA) Stock Outlook: December 11, 2025 Update on Public Offering, Atacicept BLA and Wall Street Targets - ts2.tech

Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock - GlobeNewswire

Intellia Therapeutics (NASDAQ:NTLA) Stock Rating Upgraded by Wall Street Zen - MarketBeat

Avenue Therapeutics Inc. (ATXI) Stock Price | Live Quotes & Charts | OTO - StocksToTrade

Spero Therapeutics (NASDAQ:SPRO) Stock Rating Lowered by Wall Street Zen - MarketBeat

Rapport Therapeutics (NASDAQ:RAPP) Downgraded to Sell Rating by Wall Street Zen - MarketBeat

Avenue Therapeutics (NASDAQ: ATXI) 2025 proxy on director elections, KPMG audit and Fortress control - Stock Titan

Finanzdaten der Avenue Therapeutics Inc-Aktie (ATXI)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie ATXI